NLRP3 Inflammasome Activation Inhibitors in Inflammation-Associated Cancer Immunotherapy: An Update on the Recent Patents

Publisher： Bentham Science Publishers

E-ISSN： 2212-3970|13|1|106-117

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.13, Iss.1, 2018-01, pp. : 106-117

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Polymorphism in the NLRP3 inflammasome-associated EIF2AK2 gene and inflammatory bowel disease

By          

Molecular Medicine Reports, Vol. 11, Iss. 6, 2015-01 ,pp. : 4579-4584

Spandidos Publications

Access to resources Recommend Favorite

Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer

By            

Oncology Letters, Vol. 3, Iss. 5, 2012-01 ,pp. : 1166-1170

Spandidos Publications

Access to resources Recommend Favorite

Recent Patents Therapeutic Agents for Cancer

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 1, Iss. 2, 2006-06 ,pp. : 255-284

Bentham Science Publishers

Access to resources Recommend Favorite

Immunotherapy for Prostate Cancer: Recent Developments

By So-Rosillo Rosendo   Small Eric J.  

American Journal of Cancer, Vol. 5, Iss. 5, 2006-01 ,pp. : 331-339

Adis International

Access to resources Recommend Favorite

Glycolysis Inhibitors for Anticancer Therapy: A Review of Recent Patents

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, Iss. 3, 2016-08 ,pp. : 297-308

Bentham Science Publishers

Access to resources Recommend Favorite